ALNY Alnylam Pharmaceuticals, Inc. | US02043Q1076
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 7.242.981.810 | 5.612.763.860 | 29.04% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 13,44 | 9,42 | 42.62% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 14 | 14 | 0.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |